Galapagos initiates Phase 1 study with cystic fibrosis drug GLPG2737
Galapagos NV (Euronext & NASDAQ: GLPG) reports the initiation of a Phase 1 study in healthy volunteers with GLPG2737, a novel C2 corrector drug for cystic fibrosis. Initiation of the Phase 1 study triggers a $10 million milestone payment from AbbVie.
The aim of the Phase 1 study is to evaluate the safety, tolerability and Continue reading Galapagos initiates Phase 1 study
Vertex to test new class of cystic fibrosis drugs in patients
Vertex Pharmaceuticals Inc. said Tuesday it will begin clinical trials for a new class of “triple combination” drug candidates that could nearly double the Continue reading Vertex to test new class of CF drugs
Vertex Pharmaceuticals Inc. said Monday it is ending a clinical study testing a two-drug combination therapy on a small group of cystic fibrosis patients after an independent board concluded the experimental treatment wasn’t showing Continue reading Vertex ends trial of cystic fibrosis drug combination
This GoPro video definitely shows a behind the scenes look at my life with cystic fibrosis. I tried to capture the maintenance that my body requires for it to fully function. Beyond that I really wanted to give a first person point of view of my Continue reading OWN IT: Living with CF GoPro Part II
Cystic fibrosis lung cells were restored to 50 percent of healthy function in work that provides the first evidence that novel therapeutic strategies for human patients can be identified based on yeast studies.
In experiments with isolated cystic fibrosis lung cells, University of Alabama at Continue reading Therapeutically robust correction, in vitro, of the most common cystic fibrosis mutation
Galapagos NV (Euronext & NASDAQ: GLPG) announces the start of a Phase 1 study with potentiator GLPG2451 for cystic fibrosis (CF). Following GLPG1837, GLPG2451 is the second potentiator compound in Galapagos’ extended CF-portfolio to enter clinical trials.
Galapagos is conducting a randomized, double-blind, placebo-controlled Continue reading Galapagos starts Phase 1 study with potentiator GLPG2451 for CF
While CFTR modulators have stolen the cystic fibrosis treatment spotlight, Corbus Pharmaceuticals has quietly tackled CF’s inflammatory and fibrotic components. Resunab, Corbus’s investigative agent, has the potential to Continue reading Corbus bets on cystic-fibrosis market with Resunab
Precision medicine sounds like an inarguably good thing. It begins with the observation that individuals vary in their genetic makeup and that their diseases and responses to medications differ as a result. It then aims to find the right drug, for the right patient, at the Continue reading The Paradox of Precision Medicine